Bank of America’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,081,133
| Closed | -$16.4M | – | 8714 |
|
|
2022
Q3 | $16.4M | Sell |
1,081,133
-1,518,615
| -58% | -$17.7M | ﹤0.01% | 2136 |
|
|
2022
Q2 | $19.5M | Sell |
2,599,748
-170,904
| -6% | -$1.2M | ﹤0.01% | 2047 |
|
|
2022
Q1 | $25.2M | Buy |
2,770,652
+416,759
| +18% | +$3.21M | ﹤0.01% | 1926 |
|
|
2021
Q4 | $16.5M | Sell |
2,353,893
-274,204
| -10% | -$2.87M | ﹤0.01% | 2408 |
|
|
2021
Q3 | $30M | Buy |
2,628,097
+2,190
| +0.1% | +$32K | ﹤0.01% | 1780 |
|
|
2021
Q2 | $42M | Sell |
2,625,907
-34,194
| -1% | -$587K | ﹤0.01% | 1490 |
|
|
2021
Q1 | $47.5M | Sell |
2,660,101
-339,625
| -11% | -$5.87M | 0.01% | 1336 |
|
|
2020
Q4 | $40.5M | Buy |
2,999,726
+320,016
| +12% | +$3.87M | 0.01% | 1322 |
|
|
2020
Q3 | $31.5M | Buy |
2,679,710
+455,420
| +20% | +$5.55M | ﹤0.01% | 1356 |
|
|
2020
Q2 | $32.8M | Buy |
2,224,290
+746,310
| +50% | +$11M | 0.01% | 1255 |
|
|
2020
Q1 | $20M | Buy |
1,477,980
+318,066
| +27% | +$6.03M | ﹤0.01% | 1510 |
|
|
2019
Q4 | $28M | Buy |
1,159,914
+1,099,936
| +1,834% | +$22.8M | ﹤0.01% | 1596 |
|
|
2019
Q3 | $1.15M | Buy |
59,978
+22,677
| +61% | +$520K | ﹤0.01% | 4455 |
|
|
2019
Q2 | $1.1M | Sell |
37,301
-185,931
| -83% | -$7.16M | ﹤0.01% | 4500 |
|
|
2019
Q1 | $10.6M | Sell |
223,232
-189,198
| -46% | -$8.33M | ﹤0.01% | 2431 |
|
|
2018
Q4 | $14.9M | Sell |
412,430
-185,247
| -31% | -$8.69M | ﹤0.01% | 1932 |
|
|
2018
Q3 | $36.8M | Buy |
597,677
+175,211
| +41% | +$11.3M | 0.01% | 1317 |
|
|
2018
Q2 | $28.5M | Buy |
422,466
+261,293
| +162% | +$14.6M | ﹤0.01% | 1534 |
|
|
2018
Q1 | $8.74M | Buy |
161,173
+124,358
| +338% | +$6.96M | ﹤0.01% | 2532 |
|
|
2017
Q4 | $2.2M | Sell |
36,815
-13,382
| -27% | -$811K | ﹤0.01% | 3864 |
|
|
2017
Q3 | $2.44M | Buy |
50,197
+16,063
| +47% | +$876K | ﹤0.01% | 3812 |
|
|
2017
Q2 | $1.79M | Sell |
34,134
-24,883
| -42% | -$1.16M | ﹤0.01% | 3979 |
|
|
2017
Q1 | $2.68M | Sell |
59,017
-10,327
| -15% | -$461K | ﹤0.01% | 3609 |
|
|
2016
Q4 | $2.63M | Buy |
69,344
+7,420
| +12% | +$281K | ﹤0.01% | 3540 |
|
|
2016
Q3 | $2.34M | Sell |
61,924
-1,622
| -3% | -$35.8K | ﹤0.01% | 3520 |
|
|
2016
Q2 | $1.12M | Buy |
63,546
+2,505
| +4% | +$40.6K | ﹤0.01% | 4090 |
|
|
2016
Q1 | $742K | Sell |
61,041
-18,698
| -23% | -$296K | ﹤0.01% | 4323 |
|
|
2015
Q4 | $1.94M | Sell |
79,739
-282
| -0.4% | -$6.58K | ﹤0.01% | 3822 |
|
|
2015
Q3 | $1.42M | Buy |
80,021
+38,160
| +91% | +$691K | ﹤0.01% | 4065 |
|
|
2015
Q2 | $739K | Sell |
41,861
-53,003
| -56% | -$972K | ﹤0.01% | 4370 |
|
|
2015
Q1 | $2.97M | Buy |
94,864
+72,023
| +315% | +$2.09M | ﹤0.01% | 2888 |
|
|
2014
Q4 | $668K | Sell |
22,841
-1,272
| -5% | -$32.3K | ﹤0.01% | 4370 |
|
|
2014
Q3 | $499K | Buy |
+24,113
| New | +$475K | ﹤0.01% | 4585 |
|
|
2014
Q2 | – | Sell |
-37
| Closed | -$1K | – | 8279 |
|
|
2014
Q1 | $1K | Sell |
37
-63
| -63% | -$1.27K | ﹤0.01% | 7659 |
|
|
2013
Q4 | $2K | Buy |
+100
| New | +$1.3K | ﹤0.01% | 7660 |
|
Bank of America's AERI Position: Q4 2022 in Review
Bank of America sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 1,081,133 shares — an estimated $16.4M sold.
Bank of America first reported a position in AERI in Q4 2013 and held it in 35 quarters. The position peaked at $47.5M in Q1 2021. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Bank of America reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Bank of America sold 1,081,133 Aerie Pharmaceuticals shares in Q4 2022, an estimated $16.4M.
- Bank of America first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 35 quarters.
- Bank of America's Aerie Pharmaceuticals position peaked at $47.5M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.